Affordable Care Act

Enhanced Premium tax credits

2025 KFF Marketplace Enrollees Survey

If the amount they pay in premiums doubled, about one in three enrollees in Affordable Care Act Marketplace health plans say they would be “very likely” to look for a lower-premium Marketplace plan.

An image of text is an excerpt form Larry Levitt's quick take which reads, "While the enhanced ACA premium tax credits expire at the end of this year, there is no absolute drop-dead date for extending them. ACA enrollees would welcome premium relief whenever it comes."

There is No Drop-Dead Date for an ACA Tax Credit Extension, But Coverage Losses Will Mount as the Clock Ticks

A discharge petition in the House paves the way for a vote on a three-year extension of the tax credits, which would provide ACA enrollees premium relief whenever it comes. While there is still time to extend the enhanced tax credits, with each passing day, more and more ACA Marketplace enrollees are going to drop their health insurance when faced with eye-popping increases in their premium payments, writes KFF’s Larry Levitt.

Timely insights and analysis from KFF staff

Subscribe to KFF Emails

Choose which emails are best for you.
Sign up here

Filter

701 - 710 of 2,750 Results

  • KFF Health Tracking Poll – October 2021: Home And Community Based Services And Seniors’ Health Care Needs

    Feature

    The October KFF Health Tracking Poll explores experiences with unpaid caregiving, and favorability of expansion of home and community based services (HCBS). It also examines experiences with difficulty affording and putting of health care services among seniors, favorability of the ACA and experience with determining eligibility for lower cost insurance as part of the COVID relief package.

  • The Inequity Of The Medicaid Coverage Gap and Why It Is Hard To Fix It

    Perspective

    In this column for the JAMA Health Forum, Larry Levitt explores why the Medicaid "coverage gap" still exists in 12 states that have not expanded their Medicaid programs under the Affordable Care Act, why it matters, and why eliminating it could prove challenging.

  • The Public Weighs In On Medicare Drug Negotiations

    Feature

    This data note from the latest KFF Health Tracking Poll explores the public's views on Medicare drug price negotiation, including how arguments on both sides impact support and opposition; confidence in leaders to do the right thing on drug pricing; and experiences with prescription drug costs.

  • Large Majorities Across Parties Favor Allowing the Federal Government to Negotiate Drug Prices, Even After Hearing Common Arguments About It

    News Release

    Most of the Public Lacks Confidence that President Biden, Congressional Democrats or Republicans Will Do the Right Thing on Drug Prices Allowing the federal government to negotiate with drug companies to lower drug prices for Medicare beneficiaries and people enrolled in private plans – a key cost-saving proposal in the Democrats’ massive reconciliation bill –…

  • Navigator Funding Restored in Federal Marketplace States for 2022

    Issue Brief

    This data notereviews the data from CMS about its funding awards to Navigator programs serving consumers in the federal marketplace states during the 2022 open enrollment season, as well as funding trends over time and funding by state.

  • How Marketplace Costs and Premiums will Change if Rescue Plan Subsidies Expire

    Policy Watch

    In this Policy Watch we explore the potential impact of the expiration of the American Rescue Plan Act’s enhanced financial help and new eligibility for the Affordable Care Act’s health insurance Marketplace federal subsidies. While the COVID-19 relief legislation passed earlier this year provides greater subsidy assistance through 2022, Democrats in Congress are currently considering making the temporary federal help permanent or extending it as part of their planned budget reconciliation legislation.

  • Substance Use Issues Are Worsening Alongside Access to Care

    Policy Watch

    Drug overdose deaths rose during the early part of the COVID-19 pandemic, with some of the biggest jumps occurring among people of color. This analysis breaks out drug overdose deaths by race and ethnicity for the first nine months of 2020, to the same period in each of the two prior years. It also looks at access to care issues and recent and pending legislation aimed at addressing the nation’s substance use and mental health challenges.